Daniel J Sargent

List of Publications by Year in Descending Order

348 papers	39,733 citations	85 h-index	195 g-index
365 ext. papers	45,128 ext. citations	6.9 avg, IF	6.94 L-index

#	Paper	IF	Citations
348	Clinical Outcomes in Patients With Colon Cancer With Microsatellite Instability of Sporadic or Familial Origin Treated With Adjuvant FOLFOX With or Without Cetuximab: A Pooled Analysis of the PETACC8 and N0147 Trials. *JCO Precision Oncology*, **2020**, 4,	3.6	4
347	Missing tumor measurement (TM) data in the search for alternative TM-based endpoints in cancer clinical trials. *Contemporary Clinical Trials Communications*, **2020**, 17, 100492	1.8	3
346	An adaptive multi-stage phase I dose-finding design incorporating continuous efficacy and toxicity data from multiple treatment cycles. *Journal of Biopharmaceutical Statistics*, **2019**, 29, 271-286	1.3	3
345	Disease-free Survival and Local Recurrence for Laparoscopic Resection Compared With Open Resection of Stage II to III Rectal Cancer: Follow-up Results of the ACOSOG Z6051 Randomized Controlled Trial. *Annals of Surgery*, **2019**, 269, 589-595	7.8	168
344	Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project. *Journal of the National Cancer Institute*, **2018**, 110, 638-648	9.7	63
343	Reporting of patient characteristics and stratification factors in phase 3 trials investigating first-line systemic treatment of metastatic colorectal cancer: A systematic review. *European Journal of Cancer*, **2018**, 96, 115-124	7.5	1
342	Physical Activity and Outcomes in Patients with Stage III Colon Cancer: A Correlative Analysis of Phase III Trial NCCTG N0147 (Alliance). *Cancer Epidemiology Biomarkers and Prevention*, **2018**, 27, 696-703	4	9
341	Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. *New England Journal of Medicine*, **2018**, 378, 1177-1188	59.2	429
340	A hierarchical Bayesian design for randomized Phase II clinical trials with multiple groups. *Journal of Biopharmaceutical Statistics*, **2018**, 28, 451-462	1.3	1
339	Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials. *JAMA Oncology*, **2018**, 4, 379-383	13.4	64
338	Challenges of conducting a prospective clinical trial for older patients: Lessons learned from NCCTG N0949 (alliance). *Journal of Geriatric Oncology*, **2018**, 9, 24-31	3.6	8
337	International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. *Lancet, The*, **2018**, 391, 2128-2139	40	910
336	Combining Survival and Toxicity Effect Sizes from Clinical Trials: NCCTG 89-20-52 (Alliance). *International Journal of Statistics in Medical Research*, **2018**, 7, 137-146	3	
335	Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL´and COIN-B trials in the ARCAD database. *European Journal of Cancer*, **2018**, 103, 205-213	7.5	9
334	A Bayesian dose-finding design incorporating toxicity data from multiple treatment cycles. *Statistics in Medicine*, **2017**, 36, 67-80	2.3	9
333	Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology. *Journal of Clinical Oncology*, **2017**, 35, 1453-1486	2.2	191
332	Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials. *Journal of Clinical Oncology*, **2017**, 35, 552-560	2.2	69

331	Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. *Archives of Pathology and Laboratory Medicine*, **2017**, 141, 625-657	5	54
330	Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. *Journal of Molecular Diagnostics*, **2017**, 19, 187-225	5.1	76
329	Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials. *Oncologist*, **2017**, 22, 189-198	5.7	7
328	Use of Bayesian Decision Analysis to Minimize Harm in Patient-Centered Randomized Clinical Trials in Oncology. *JAMA Oncology*, **2017**, 3, e170123	13.4	14
327	Molecular Biomarkers for the Evaluation of Colorectal Cancer. *American Journal of Clinical Pathology*, **2017**, 147, 221-260	1.9	19
326	Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials. *JAMA Oncology*, **2017**, 3, 472-480	13.4	59
325	Prognostic Value of BRAF´and´KRAS´Mutations in MSI and MSS Stage III Colon Cancer. *Journal of the National Cancer Institute*, **2017**, 109,	9.7	138
324	Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis. *Lancet Oncology, The*, **2017**, 18, 143-154	21.7	45
323	Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline Summary From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. *Journal of Oncology Practice*, **2017**, 13, 333-337	3.1	20
322	Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database. *Journal of Clinical Oncology*, **2017**, 35, 1929-1937	2.2	28
321	Family history of colorectal cancer and its impact on survival in patients with resected stage III colon cancer: results from NCCTG Trial N0147 (Alliance). *Journal of Gastrointestinal Oncology*, **2017**, 8, 1-11	2.8	7
320	The Search for Surrogate Endpoints in Trials in Diffuse Large B-Cell Lymphoma: The Surrogate Endpoints for Aggressive Lymphoma Project. *Oncologist*, **2017**, 22, 1415-1418	5.7	5
319	Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data. *Clinical Trials*, **2017**, 14, 611-620	2.2	4
318	Lack of Caudal-Type Homeobox Transcription Factor 2 Expression as a Prognostic Biomarker in Metastatic Colorectal Cancer. *Clinical Colorectal Cancer*, **2017**, 16, 124-128	3.8	28
317	Association of immune markers and Immunoscore with survival of stage III colon carcinoma (CC) patients (pts) treated with adjuvant FOLFOX: NCCTG N0147 (Alliance).. *Journal of Clinical Oncology*, **2017**, 35, 3579-3579	2.2	8
316	Colon and Rectum **2017**, 251-274		35
315	Analysis of serum vitamin D levels and prognosis in stage III colon carcinoma patients treated with adjuvant FOLFOX+/- cetuximab chemotherapy: NCCTG N0147 (Alliance).. *Journal of Clinical Oncology*, **2017**, 35, 3516-3516	2.2	
314	Further Evaluating the Benefit of Adjuvant Chemotherapy for Colon Cancer. *Journal of Clinical Oncology*, **2016**, 34, 3711-3712	2.2	3

313	Beyond Composite Endpoints Analysis: Semicompeting Risks as an Underutilized Framework for Cancer Research. *Journal of the National Cancer Institute*, **2016**, 108,	9.7	14
312	Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance). *Oncologist*, **2016**, 21, 1509-1521	5.7	24
311	Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance). *Pharmacogenetics and Genomics*, **2016**, 26, 133-7	1.9	19
310	Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. *Lancet Oncology, The*, **2016**, 17, 1709-1719	21.7	258
309	Flexible Bayesian survival modeling with semiparametric time-dependent and shape-restricted covariate effects. *Bayesian Analysis*, **2016**, 11, 381-402	2.3	16
308	Testing of evaluation bias for progression free survival endpoint in oncology clinical trials. *Statistics in Medicine*, **2016**, 35, 3923-32	2.3	
307	New insights into the evaluation of randomized controlled trials for rare diseases over a long-term research horizon: a simulation study. *Statistics in Medicine*, **2016**, 35, 3245-58	2.3	6
306	Clinical trial designs incorporating predictive biomarkers. *Cancer Treatment Reviews*, **2016**, 43, 74-82	14.4	44
305	Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database. *Journal of Clinical Oncology*, **2016**, 34, 1182-9	2.2	22
304	Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database. *Journal of Clinical Oncology*, **2016**, 34, 843-53	2.2	90
303	Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database. *Journal of Clinical Oncology*, **2016**, 34, 144-50	2.2	76
302	Outcomes for Elderly Patients (pts) with Follicular Lymphoma (FL) Using Individual Patient Data (IPD) from 5922 Pts in 18 Randomized Controlled Trials (RCTs): a Follicular Lymphoma Analysis of Surrogate Hypothesis (FLASH) Group Study. *Blood*, **2016**, 128, 1102-1102	2.2	2
301	Utility of Progression-Free Survival at 24 Months (PFS24) to Predict Subsequent Outcome for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Enrolled on Randomized Clinical Trials: Findings from a Surrogate Endpoint in Aggressive Lymphoma (SEAL) Analysis of Individual Patient Data from 5853 Patients. *Blood*, **2016**, 128, 3027-3027	2.2	4
300	Evaluation of Progression-Free Survival (PFS) As a Surrogate Endpoint for Overall Survival (OS) in First-Line Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): Findings from the Surrogate Endpoint in Aggressive Lymphoma (SEAL) Analysis of Individual Patient Data from 7507 Patients. *Blood*, **2016**, 128, 4196-4196	2.2	1
299	Findings from the Adjuvant Colon Cancer End Points (ACCENT) Collaborative Group: the power of pooled individual patient data from multiple clinical trials. *Chinese Clinical Oncology*, **2016**, 5, 80	2.3	2
298	Statistics and Clinical Trials **2016**, 239-252.e1		
297	Alcohol consumption and colon cancer prognosis among participants in north central cancer treatment group phase III trial N0147. *International Journal of Cancer*, **2016**, 139, 986-95	7.5	11
296	Surrogate End Points in Soft Tissue Sarcoma: Methodologic Challenges. *Journal of Clinical Oncology* , **2016**, 34, 3949-3950	2.2	3

295	Validity of Adjuvant! Online in older patients with stage III colon cancer based on 2967 patients from the ACCENT database. *Journal of Geriatric Oncology*, **2016**, 7, 422-429	3.6	6
294	Findings from the Adjuvant Colon Cancer End Points (ACCENT) Collaborative Group: the Power of Pooled Individual Patient Data from Multiple Clinical Trials. *Current Colorectal Cancer Reports*, **2016**, 12, 251-259	1	
293	American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine. *Ca-A Cancer Journal for Clinicians*, **2016**, 66, 370-4	220.7	219
292	Racial Differences in BRAF/KRAS Mutation Rates and Survival in Stage III Colon Cancer Patients. *Journal of the National Cancer Institute*, **2015**, 107,	9.7	67
291	Improved Outcomes in Metastatic Colon Cancer: Giving Credit Where Credit Is Due. *JAMA Oncology*, **2015**, 1, 795-6	13.4	2
290	Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. *Lancet Oncology, The*, **2015**, 16, 937-48	21.7	240
289	Prognostic Value of Molecular Detection of Lymph Node Metastases After Curative Resection of Stage II Colon Cancer: A Systematic Pooled Data Analysis. *Clinical Colorectal Cancer*, **2015**, 14, 99-105	3.8	2
288	Impact of Copula Directional Specification on Multi-Trial Evaluation of Surrogate End Points. *Journal of Biopharmaceutical Statistics*, **2015**, 25, 857-77	1.3	6
287	Genotype-based clinical trials in cardiovascular disease. *Nature Reviews Cardiology*, **2015**, 12, 475-87	14.8	31
286	Clinical Utility of Metrics Based on Tumor Measurements in Phase II Trials to Predict Overall Survival Outcomes in Phase III Trials by Using Resampling Methods. *Journal of Clinical Oncology*, **2015**, 33, 4048-57	2.2	6
285	Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance). *Clinical Cancer Research*, **2015**, 21, 5294-304	12.9	53
284	Effect of Laparoscopic-Assisted Resection vs Open Resection of Stage II or III Rectal Cancer on Pathologic Outcomes: The ACOSOG Z6051 Randomized Clinical Trial. *JAMA - Journal of the American Medical Association*, **2015**, 314, 1346-55	27.4	666
283	The Fundamental Difficulty With Evaluating the Accuracy of Biomarkers for Guiding Treatment. *Journal of the National Cancer Institute*, **2015**, 107,	9.7	19
282	Validation of survival prognostic models for non-small-cell lung cancer in stage- and age-specific groups. *Lung Cancer*, **2015**, 90, 281-7	5.9	5
281	New Adjuvant Trial Designs in Colon Cancer. *Current Colorectal Cancer Reports*, **2015**, 11, 326-334	1	2
280	Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes. *Gastroenterology*, **2015**, 148, 88-99	13.3	219
279	Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database. *Journal of Clinical Oncology*, **2015**, 33, 22-8	2.2	69
278	The direct assignment option as a modular design component: an example for the setting of two predefined subgroups. *Computational and Mathematical Methods in Medicine*, **2015**, 2015, 210817	2.8	2

277	Evaluating Continuous Tumor Measurement-Based Metrics as Phase II Endpoints for Predicting Overall Survival. *Journal of the National Cancer Institute*, **2015**, 107,	9.7	16
276	Resampling the N9741 trial to compare tumor dynamic versus conventional end points in randomized phase II trials. *Journal of Clinical Oncology*, **2015**, 33, 36-41	2.2	12
275	Raising the bar for antineoplastic agents: how to choose threshold values for superiority trials in advanced solid tumors. *Clinical Cancer Research*, **2015**, 21, 1036-43	12.9	23
274	Comparing and Validating Simple Measures of Patient-Reported Peripheral Neuropathy for Oncology Clinical Trials: NCCTG N0897 (Alliance) A Pooled Analysis of 2440 Patients **2015**, 2,		5
273	Introduction to special issue on biomarker-based clinical trial designs in oncology. *Chinese Clinical Oncology*, **2015**, 4, 28	2.3	
272	Comparison of FOLFIRI with or without cetuximab in patients with resected stage III colon cancer; NCCTG (Alliance) intergroup trial N0147. *Clinical Colorectal Cancer*, **2014**, 13, 100-9	3.8	36
271	KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance). *Clinical Cancer Research*, **2014**, 20, 3033-43	12.9	105
270	Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. *Journal of Clinical Oncology*, **2014**, 32, 1031-9	2.2	164
269	Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147. *Journal of the National Cancer Institute*, **2014**, 106,	9.7	109
268	American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. *Journal of Clinical Oncology*, **2014**, 32, 1277-80	2.2	273
267	Evaluation of alternate categorical tumor metrics and cut points for response categorization using the RECIST 1.1 data warehouse. *Journal of Clinical Oncology*, **2014**, 32, 841-50	2.2	35
266	Center-Within-Trial Versus Trial-Level Evaluation of Surrogate Endpoints. *Computational Statistics and Data Analysis*, **2014**, 78, 1-20	1.6	10
265	Calibration of quality-adjusted life years for oncology clinical trials. *Journal of Pain and Symptom Management*, **2014**, 47, 1091-1099.e3	4.8	6
264	Exploring the statistical and clinical impact of two interim analyses on the Phase II design with option for direct assignment. *Contemporary Clinical Trials*, **2014**, 38, 157-62	2.3	1
263	Projecting Event-Based Analysis Dates in Clinical Trials: An Illustration Based on the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) Collaboration. Projecting analysis dates for the IDEA collaboration. *Forum of Clinical Oncology*, **2014**, 5, 1-7	0.3	1
262	Biomarker-driven Studies in Metastatic Colorectal Cancer (mCRC): Challenges and Opportunities. *The Journal of Oncopathology*, **2014**, 2, 37-45		
261	Randomized phase II clinical trials. *Journal of Biopharmaceutical Statistics*, **2014**, 24, 802-16	1.3	8
260	Association study of the let-7 miRNA-complementary site variant in the 3′untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial). *Clinical Cancer Research*, **2014**, 20, 3319-27	12.9	36

259	DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147). *Journal of the National Cancer Institute*, **2014**, 106,	9.7	101
258	Association of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD Clinical Trials Program. *Journal of Clinical Oncology*, **2014**, 32, 2975-84	2.2	77
257	Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee. *Clinical Cancer Research*, **2014**, 20, 4210-7	12.9	41
256	Molecular testing for lymph node metastases as a determinant of colon cancer recurrence: results from a retrospective multicenter study. *Clinical Cancer Research*, **2014**, 20, 4361-9	12.9	18
255	ACCENT-based web calculators to predict recurrence and overall survival in stage III colon cancer. *Journal of the National Cancer Institute*, **2014**, 106,	9.7	48
254	The role of response evaluation criteria in solid tumour in anticancer treatment evaluation: results of a survey in the oncology community. *European Journal of Cancer*, **2014**, 50, 260-6	7.5	26
253	Germline variation in colorectal risk Loci does not influence treatment effect or survival in metastatic colorectal cancer. *PLoS ONE*, **2014**, 9, e94727	3.7	3
252	Drug designs fulfilling the requirements of clinical trials aiming at personalizing medicine. *Chinese Clinical Oncology*, **2014**, 3, 14	2.3	9
251	Adaptive randomized phase II design for biomarker threshold selection and independent evaluation. *Chinese Clinical Oncology*, **2014**, 3,	2.3	5
250	Drug rechallenge and treatment beyond progression--implications for drug resistance. *Nature Reviews Clinical Oncology*, **2013**, 10, 571-87	19.4	174
249	Statistical issues in the validation of prognostic, predictive, and surrogate biomarkers. *Clinical Trials* , **2013**, 10, 647-52	2.2	21
248	Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. *Lancet, The*, **2013**, 381, 303-12	40	1783
247	Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy. *Journal of Clinical Oncology*, **2013**, 31, 3664-72	2.2	192
246	Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis. *Journal of the National Cancer Institute*, **2013**, 105, 1667-70	9.7	58
245	Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysis. *European Journal of Cancer*, **2013**, 49, 1565-77	7.5	119
244	The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6´months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status. *Current Colorectal Cancer Reports*, **2013**, 9, 261-269	1	82
243	Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy. *Cancer*, **2013**, 119, 1528-36	6.4	104
242	Current use and surgical efficacy of laparoscopic colectomy in colon cancer. *Journal of the American College of Surgeons*, **2013**, 217, 56-62; discussion 62-3	4.4	13

241	Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis. *Journal of the National Cancer Institute*, **2013**, 105, 1600-7	9.7	102
240	A phase II flexible screening design allowing for interim analysis and comparison with historical control. *Contemporary Clinical Trials*, **2013**, 35, 128-37	2.3	1
239	A review of phase II trial designs for initial marker validation. *Contemporary Clinical Trials*, **2013**, 36, 597-604	2.3	20
238	The predictive and prognostic value of sex in early-stage colon cancer: a pooled analysis of 33,345 patients from the ACCENT database. *Clinical Colorectal Cancer*, **2013**, 12, 179-87	3.8	22
237	Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database. *Journal of Clinical Oncology*, **2013**, 31, 2600-6	2.2	171
236	Comparison of outcomes after fluorouracil-based adjuvant therapy for stages II and III colon cancer between 1978 to 1995 and 1996 to 2007: evidence of stage migration from the ACCENT database. *Journal of Clinical Oncology*, **2013**, 31, 3656-63	2.2	56
235	Adaptive adjustment of the randomization ratio using historical control data. *Clinical Trials*, **2013**, 10, 430-40	2.2	63
234	Associations between cigarette smoking status and colon cancer prognosis among participants in North Central Cancer Treatment Group Phase III Trial N0147. *Journal of Clinical Oncology*, **2013**, 31, 2016-23	2.2	42
233	Application of tumor measurement-based metrics in the real world. *Journal of Clinical Oncology*, **2013**, 31, 4374	2.2	3
232	Disease-free survival in colon cancer: still relevant after all these years!. *Journal of Clinical Oncology*, **2013**, 31, 1609-10	2.2	9
231	Surgical quality surrogates do not predict colon cancer survival in the setting of technical credentialing: a report from the prospective COST trial. *Annals of Surgery*, **2013**, 257, 102-7	7.8	20
230	Mining the ACCENT database: a review and update. *Chinese Clinical Oncology*, **2013**, 2, 18	2.3	5
229	Clinical Validation of Biomarkers **2013**, 353-367		
228	Adjuvant treatment of stage II colon cancer: yes or no, what, when and why? **2013**, 6-19		
227	Exploring racial differences in outcome and treatment for metastatic colorectal cancer: results from a large prospective observational cohort study (BRiTE). *Cancer*, **2012**, 118, 1083-90	6.4	29
226	Commensurate Priors for Incorporating Historical Information in Clinical Trials Using General and Generalized Linear Models. *Bayesian Analysis*, **2012**, 7, 639-674	2.3	92
225	CRM Trials for Assessing Toxicity and Efficacy **2012**, 85-96		0
224	Phase 2 trial design in neuro-oncology revisited: a report from the RANO group. *Lancet Oncology, The*, **2012**, 13, e196-204	21.7	43

223	Predictive biomarkers in colorectal cancer: usage, validation, and design in clinical trials. *Scandinavian Journal of Gastroenterology*, **2012**, 47, 356-62	2.4	12
222	Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications. *Clinical Cancer Research*, **2012**, 18, 1506-12	12.9	176
221	Meta-analysis for surrogacy: accelerated failure time models and semicompeting risks modeling. *Biometrics*, **2012**, 68, 226-32	1.8	13
220	Rejoinder for "Meta-analysis for surrogacy: accelerated failure time models and semi-competing risks modelling". *Biometrics*, **2012**, 68, 245-247	1.8	2
219	Predicting treatment effect from surrogate endpoints and historical trials: an extrapolation involving probabilities of a binary outcome or survival to a specific time. *Biometrics*, **2012**, 68, 248-57	1.8	12
218	Bayesian adaptive trial design for a newly validated surrogate endpoint. *Biometrics*, **2012**, 68, 258-67	1.8	7
217	Prognostic impact of FoxP3+ regulatory T cells in relation to CD8+ T lymphocyte density in human colon carcinomas. *PLoS ONE*, **2012**, 7, e42274	3.7	73
216	Bayesian adjusted R2 for the meta-analytic evaluation of surrogate time-to-event endpoints in clinical trials. *Statistics in Medicine*, **2012**, 31, 743-61	2.3	22
215	On Bayesian methods of exploring qualitative interactions for targeted treatment. *Statistics in Medicine*, **2012**, 31, 3693-707	2.3	10
214	Taking the long view: how to design a series of Phase III trials to maximize cumulative therapeutic benefit. *Clinical Trials*, **2012**, 9, 283-92	2.2	16
213	Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. *JAMA - Journal of the American Medical Association*, **2012**, 307, 1383-93	27.4	330
212	Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer. *Journal of the National Cancer Institute*, **2012**, 104, 211-27	9.7	77
211	Benefits and adverse events in younger versus older patients receiving adjuvant chemotherapy for colon cancer: findings from the Adjuvant Colon Cancer Endpoints data set. *Journal of Clinical Oncology*, **2012**, 30, 2334-9	2.2	24
210	Reply to S.A. Kesikli et al. *Journal of Clinical Oncology*, **2012**, 30, 2288-2289	2.2	1
209	A 2-stage phase II design with direct assignment option in stage II for initial marker validation. *Clinical Cancer Research*, **2012**, 18, 4225-33	12.9	13
208	Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. *Journal of Clinical Oncology*, **2012**, 30, 263-7	2.2	380
207	Association of obesity with DNA mismatch repair status and clinical outcome in patients with stage II or III colon carcinoma participating in NCCTG and NSABP adjuvant chemotherapy trials. *Journal of Clinical Oncology*, **2012**, 30, 406-12	2.2	38
206	Achieving sufficient accrual to address the primary endpoint in phase III clinical trials from U.S. Cooperative Oncology Groups. *Clinical Cancer Research*, **2012**, 18, 256-62	12.9	41

205	The ARCAD clinical trials program: an update and invitation. *Oncologist*, **2012**, 17, 188-91	5.7	4
204	A phase II trial design with direct assignment option for initial marker validation.. *Journal of Clinical Oncology*, **2012**, 30, 34-34	2.2	1
203	Statistics and Clinical Trials **2012**, 223-237		
202	Optimism bias leads to inconclusive results-an empirical study. *Journal of Clinical Epidemiology*, **2011**, 64, 583-93	5.7	34
201	All-comers versus enrichment design strategy in phase II trials. *Journal of Thoracic Oncology*, **2011**, 6, 658-60	8.9	19
200	Hierarchical commensurate and power prior models for adaptive incorporation of historical information in clinical trials. *Biometrics*, **2011**, 67, 1047-56	1.8	173
199	Statistical considerations for the next generation of clinical trials. *Seminars in Oncology*, **2011**, 38, 598-604	3.5	8
198	Long-term follow-up and individual item analysis of quality of life assessments related to laparoscopic-assisted colectomy in the COST trial 93-46-53 (INT 0146). *Annals of Surgical Oncology*, **2011**, 18, 2422-31	3.1	54
197	Evaluation of guanylyl cyclase C lymph node status for colon cancer staging and prognosis. *Annals of Surgical Oncology*, **2011**, 18, 3261-70	3.1	29
196	Incorporation of biomarker assessment in novel clinical trial designs: personalizing brain tumor treatments. *Current Oncology Reports*, **2011**, 13, 42-9	6.3	19
195	Prognostic web-based models for stage II and III colon cancer: A population and clinical trials-based validation of numeracy and adjuvant! online. *Cancer*, **2011**, 117, 4155-65	6.4	21
194	Impact of young age on treatment efficacy and safety in advanced colorectal cancer: a pooled analysis of patients from nine first-line phase III chemotherapy trials. *Journal of Clinical Oncology*, **2011**, 29, 2781-6	2.2	38
193	Integrating biomarkers in clinical trials. *Expert Review of Molecular Diagnostics*, **2011**, 11, 171-82	3.8	104
192	DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. *Journal of the National Cancer Institute*, **2011**, 103, 863-75	9.7	390
191	Comparative assessment of trial-level surrogacy measures for candidate time-to-event surrogate endpoints in clinical trials. *Computational Statistics and Data Analysis*, **2011**, 55, 2748-2757	1.6	21
190	Design of clinical trials for biomarker research in oncology. *Clinical Investigation*, **2011**, 1, 1629-1636		19
189	Alternative end points to evaluate a therapeutic strategy in advanced colorectal cancer: evaluation of progression-free survival, duration of disease control, and time to failure of strategy--an Aide et Recherche en Cancerologie Digestive Group Study. *Journal of Clinical Oncology*, **2011**, 29, 4199-204	2.2	45
188	Comparison of continuous versus categorical tumor measurement-based metrics to predict overall survival in cancer treatment trials. *Clinical Cancer Research*, **2011**, 17, 6592-9	12.9	22

187	Tumor status at 12 weeks predicts survival in advanced colorectal cancer: findings from NCCTG N9741. *Oncologist*, **2011**, 16, 859-67	5.7	13
186	Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials. *Journal of the National Cancer Institute*, **2011**, 103, 1498-506	9.7	47
185	Time to initiation of adjuvant chemotherapy and survival in colorectal cancer. *JAMA - Journal of the American Medical Association*, **2011**, 306, 1199; author reply 1200	27.4	8
184	Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissue. *Journal of Clinical Oncology*, **2011**, 29, 4620-6	2.2	131
183	Systemic therapy for elderly patients with gastrointestinal cancer. *Clinical Medicine Insights: Oncology*, **2011**, 5, 89-99	1.8	2
182	Using cure models and multiple imputation to utilize recurrence as an auxiliary variable for overall survival. *Clinical Trials*, **2011**, 8, 581-90	2.2	7
181	Survival is not a good outcome for randomized trials with effective subsequent therapies. *Journal of Clinical Oncology*, **2011**, 29, 4719-20; author reply 4720-1	2.2	28
180	Vitamin D status in patients with stage IV colorectal cancer: findings from Intergroup trial N9741. *Journal of Clinical Oncology*, **2011**, 29, 1599-606	2.2	71
179	Challenges to accrual predictions to phase III cancer clinical trials: a survey of study chairs and lead statisticians of 248 NCI-sponsored trials. *Clinical Trials*, **2011**, 8, 591-600	2.2	12
178	Causal assessment of surrogacy in a meta-analysis of colorectal cancer trials. *Biostatistics*, **2011**, 12, 478-92	3.7	27
177	Phase III Clinical Trials with Anticancer Agents **2011**, 163-188		
176	Biomarkers-guided targeted drugs: new clinical trials design and practice necessity **2011**, 30-41		1
175	Comparison of error rates in single-arm versus randomized phase II cancer clinical trials. *Journal of Clinical Oncology*, **2010**, 28, 1936-41	2.2	72
174	Clinical trials data collection: when less is more. *Journal of Clinical Oncology*, **2010**, 28, 5019-21	2.2	8
173	Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials. *Clinical Trials*, **2010**, 7, 312-21	2.2	74
172	Obesity is an independent prognostic variable in colon cancer survivors. *Clinical Cancer Research*, **2010**, 16, 1884-93	12.9	160
171	Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. *JAMA - Journal of the American Medical Association*, **2010**, 303, 1729-37	27.4	586
170	Reply to D.J. Stewart. *Journal of Clinical Oncology*, **2010**, 28, e652-e653	2.2	3

169	Reply to M.A. Rosen et al. *Journal of Clinical Oncology*, **2010**, 28, e161-e161	2.2	1
168	Toward efficient trials in colorectal cancer: the ARCAD Clinical Trials Program. *Journal of Clinical Oncology*, **2010**, 28, 527-30	2.2	18
167	Comparison of histopathology and RT-qPCR amplification of guanylyl cyclase C for detection of colon cancer metastases in lymph nodes. *Journal of Clinical Pathology*, **2010**, 63, 530-7	3.9	28
166	Reply to C.D. Atkins. *Journal of Clinical Oncology*, **2010**, 28, e747-e747	2.2	
165	Reply to P. Prassopoulos et al. *Journal of Clinical Oncology*, **2010**, 28, e82-e82	2.2	
164	Blinded independent central review of the progression-free survival endpoint. *Oncologist*, **2010**, 15, 492-57		28
163	Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set. *Journal of Clinical Oncology*, **2010**, 28, 460-5	2.2	49
162	Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. *Journal of Clinical Oncology*, **2010**, 28, 3219-26	2.2	1063
161	Revised tumor and node categorization for rectal cancer based on surveillance, epidemiology, and end results and rectal pooled analysis outcomes. *Journal of Clinical Oncology*, **2010**, 28, 256-63	2.2	177
160	Evaluation of the value of attribution in the interpretation of adverse event data: a North Central Cancer Treatment Group and American College of Surgeons Oncology Group investigation. *Journal of Clinical Oncology*, **2010**, 28, 3002-7	2.2	38
159	Reply to I.D. Nagtegaal et al. *Journal of Clinical Oncology*, **2010**, 28, e399-e400	2.2	
158	The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee. *Clinical Cancer Research*, **2010**, 16, 1764-9	12.9	117
157	Causal Effects of Treatments for Informative Missing Data due to Progression/Death. *Journal of the American Statistical Association*, **2010**, 105, 912-929	2.8	8
156	Designing a randomized clinical trial to evaluate personalized medicine: a new approach based on risk prediction. *Journal of the National Cancer Institute*, **2010**, 102, 1756-9	9.7	12
155	What constitutes reasonable evidence of efficacy and effectiveness to guide oncology treatment decisions?. *Oncologist*, **2010**, 15 Suppl 1, 19-23	5.7	27
154	Biomarkers and surrogate end points--the challenge of statistical validation. *Nature Reviews Clinical Oncology*, **2010**, 7, 309-17	19.4	240
153	Revised TN categorization for colon cancer based on national survival outcomes data. *Journal of Clinical Oncology*, **2010**, 28, 264-71	2.2	397
152	Randomized phase II trials: inevitable or inadvisable?. *Journal of Clinical Oncology*, **2010**, 28, 2641-7	2.2	61

151	Randomized phase II trials: time for a new era in clinical trial design. *Journal of Thoracic Oncology*, **2010**, 5, 932-4	8.9	46
150	Older versus younger patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and stomach: a pooled analysis of eight consecutive North Central Cancer Treatment Group (NCCTG) trials. *International Journal of Oncology*, **2010**, 36, 601-6	4.4	31
149	Adjuvant therapy for colon cancer: learning from the past to inform the future. *Annals of Surgical Oncology*, **2010**, 17, 947-9	3.1	5
148	Predictive biomarker validation in practice: lessons from real trials. *Clinical Trials*, **2010**, 7, 567-73	2.2	68
147	Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. *Journal of Clinical Oncology*, **2010**, 28, 3227-33	2.2	182
146	Model-based prediction of defective DNA mismatch repair using clinicopathological variables in sporadic colon cancer patients. *Cancer*, **2010**, 116, 1691-8	6.4	19
145	Model-based phase I designs incorporating toxicity and efficacy for single and dual agent drug combinations: methods and challenges. *Statistics in Medicine*, **2010**, 29, 1077-83	2.3	47
144	Leveraging learning from a phase III colorectal cancer clinical trial: outcomes, methodology, meta-analysis and pharmacogenetics. *Transactions of the American Clinical and Climatological Association*, **2010**, 121, 21-32; discussion 32-3	0.9	2
143	CAUSAL EFFECTS OF TREATMENTS FOR INFORMATIVE MISSING DATA DUE TO PROGRESSION/DEATH. *Journal of the American Statistical Association*, **2010**, 105, 912-929	2.8	6
142	Clinical Validation of Biomarkers in Cancer **2010**, 227-250		
141	Functional and clinical significance of variants localized to 8q24 in colon cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2009**, 18, 2492-500	4	36
140	Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer. *Journal of Clinical Oncology*, **2009**, 27, 1948-55	2.2	125
139	Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. *Journal of Clinical Oncology*, **2009**, 27, 3677-83	2.2	955
138	Early stopping for benefit in National Cancer Institute-sponsored randomized Phase III trials: the system is working. *Journal of Clinical Oncology*, **2009**, 27, 1543-4	2.2	5
137	Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. *Journal of Clinical Oncology*, **2009**, 27, 872-7	2.2	400
136	Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841. *Journal of Clinical Oncology*, **2009**, 27, 2848-54	2.2	56
135	Role of sensitivity analyses in assessing progression-free survival in late-stage oncology trials. *Journal of Clinical Oncology*, **2009**, 27, 5958-64	2.2	33
134	Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in north central cancer treatment group study N0147. *Oncology*, **2009**, 77, 120-3	3.6	53

133	Current issues in oncology drug development, with a focus on Phase II trials. *Journal of Biopharmaceutical Statistics*, **2009**, 19, 556-62	1.3	17
132	Clinical trial designs for predictive biomarker validation: one size does not fit all. *Journal of Biopharmaceutical Statistics*, **2009**, 19, 530-42	1.3	92
131	Evaluation of the optimal number of lesions needed for tumor evaluation using the response evaluation criteria in solid tumors: a north central cancer treatment group investigation. *Journal of Clinical Oncology*, **2009**, 27, 3205-10	2.2	31
130	NCCTG Study N9741: leveraging learning from an NCI Cooperative Group phase III trial. *Oncologist*, **2009**, 14, 970-8	5.7	10
129	Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial. *Journal of Clinical Oncology*, **2009**, 27, 4109-15	2.2	66
128	Postoperative surveillance recommendations for early stage colon cancer based on results from the clinical outcomes of surgical therapy trial. *Journal of Clinical Oncology*, **2009**, 27, 3671-6	2.2	79
127	Reply to F. Montagnani et al. *Journal of Clinical Oncology*, **2009**, 27, e134-e135	2.2	
126	Alternate endpoints for screening phase II studies. *Clinical Cancer Research*, **2009**, 15, 1873-82	12.9	68
125	Cost implications of new treatments for advanced colorectal cancer. *Cancer*, **2009**, 115, 2081-91	6.4	51
124	Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trials. *International Journal of Clinical Oncology*, **2009**, 14, 102-11	4.2	55
123	Evolving end points for clinical trials in advanced colorectal cancer. *Current Colorectal Cancer Reports*, **2009**, 5, 135-139	1	1
122	Bayesian variable selection with joint modeling of categorical and survival outcomes: an application to individualizing chemotherapy treatment in advanced colorectal cancer. *Biometrics*, **2009**, 65, 1030-40	1.8	13
121	Optimising the design of phase II oncology trials: the importance of randomisation. *European Journal of Cancer*, **2009**, 45, 275-80	7.5	98
120	Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma. *Gastroenterology*, **2009**, 137, 1270-9	13.3	229
119	Long-term survivors of metastatic colorectal cancer treated with systemic chemotherapy alone: a north central cancer treatment group review of 3811 patients, n0144. *Clinical Colorectal Cancer*, **2009**, 8, 88-93	3.8	52
118	Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. *Journal of Clinical Oncology*, **2009**, 27, 4027-34	2.2	302
117	Clinical implications of microsatellite instability in sporadic colon cancers. *Current Opinion in Oncology*, **2009**, 21, 369-73	4.2	72
116	Reply to M. Chao et al. *Journal of Clinical Oncology*, **2009**, 27, e281-e281	2.2	0

115	Long-term survivors of metastatic colorectal cancer treated with systemic chemotherapy alone: a North Central Cancer Treatment Group review of 3811 patients, N0144. *Clinical Colorectal Cancer*, **2009**, 8, 88-93	3.8	
114	Importance of randomization in early clinical trials. *Clinical Advances in Hematology and Oncology*, **2009**, 7, 249-51	0.6	
113	North Central Cancer Treatment Group--achievements and perspectives. *Seminars in Oncology*, **2008**, 35, 530-44	5.5	4
112	Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis. *Cancer Investigation*, **2008**, 26, 439-44	2.1	12
111	Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). *Journal of Clinical Oncology*, **2008**, 26, 5326-34	2.2	561
110	Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. *Clinical Cancer Research*, **2008**, 14, 3408-15	12.9	193
109	Prognostic impact of bim, puma, and noxa expression in human colon carcinomas. *Clinical Cancer Research*, **2008**, 14, 5810-8	12.9	63
108	Surrogate endpoint validation: statistical elegance versus clinical relevance. *Statistical Methods in Medical Research*, **2008**, 17, 477-86	2.3	24
107	Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. *Journal of Clinical Oncology*, **2008**, 26, 183-9	2.2	153
106	Assessing the measure of a new drug: is survival the only thing that matters?. *Journal of Clinical Oncology*, **2008**, 26, 1922-3	2.2	66
105	Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. *Journal of Clinical Oncology*, **2008**, 26, 5721-7	2.2	229
104	Proapoptotic Bad and Bid protein expression predict survival in stages II and III colon cancers. *Clinical Cancer Research*, **2008**, 14, 4128-33	12.9	35
103	Plasma insulin-like growth factors, insulin-like binding protein-3, and outcome in metastatic colorectal cancer: results from intergroup trial N9741. *Clinical Cancer Research*, **2008**, 14, 8263-9	12.9	50
102	Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set. *Journal of Clinical Oncology*, **2008**, 26, 2336-41	2.2	153
101	Surgeon volume does not predict outcomes in the setting of technical credentialing: results from a randomized trial in colon cancer. *Annals of Surgery*, **2008**, 248, 746-50	7.8	55
100	Individual data pooled analyses to improve understanding of adjuvant therapy in colon cancer: Review of the ACCENT collaborative group. *Current Colorectal Cancer Reports*, **2008**, 4, 155-159	1	1
99	A false-discovery-rate-based loss framework for selection of interactions. *Statistics in Medicine*, **2008**, 27, 2004-21	2.3	3
98	Systematic review of statistical methods used in molecular marker studies in cancer. *Cancer*, **2008**, 112, 1862-8	6.4	30

97	Genomic classifiers in colon cancer - clinical utility. *Gastrointestinal Cancer Research: GCR*, **2008**, 2, S35-7		1
96	FDG-PET lymphoma demonstration project invitational workshop. *Academic Radiology*, **2007**, 14, 330-9	4.3	25
95	Alterations in cell proliferation and apoptosis in colon cancers with microsatellite instability. *International Journal of Cancer*, **2007**, 120, 1232-8	7.5	27
94	Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal cancer. *Cancer*, **2007**, 110, 670-7	6.4	27
93	Prediction of radial distance of extraprostatic extension from pretherapy factors. *International Journal of Radiation Oncology Biology Physics*, **2007**, 69, 411-8	4	17
92	Method for evaluating prediction models that apply the results of randomized trials to individual patients. *Trials*, **2007**, 8, 14	2.8	67
91	An adaptive phase I design for identifying a biologically optimal dose for dual agent drug combinations. *Statistics in Medicine*, **2007**, 26, 2317-30	2.3	58
90	Progression-free survival is a surrogate for survival in advanced colorectal cancer. *Journal of Clinical Oncology*, **2007**, 25, 5218-24	2.2	278
89	Adjuvant therapy in the elderly: making the right decision. *Journal of Clinical Oncology*, **2007**, 25, 1870-5	2.2	68
88	Smoothing Balanced Single-Error-Term Analysis of Variance. *Technometrics*, **2007**, 49, 12-25	1.4	22
87	Priorities in colorectal cancer research: recommendations from the Gastrointestinal Scientific Leadership Council of the Coalition of Cancer Cooperative Groups. *Journal of Clinical Oncology*, **2007**, 25, 2313-21	2.2	19
86	Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741. *Journal of Clinical Oncology*, **2007**, 25, 3469-74	2.2	56
85	End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. *Journal of Clinical Oncology*, **2007**, 25, 4569-74	2.2	183
84	End points in advanced colon cancer clinical trials: a review and proposal. *Journal of Clinical Oncology*, **2007**, 25, 3572-5	2.2	61
83	Laparoscopically assisted vs open colectomy for colon cancer: a meta-analysis. *Archives of Surgery*, **2007**, 142, 298-303		406
82	Laparoscopic colectomy for cancer is not inferior to open surgery based on 5-year data from the COST Study Group trial. *Annals of Surgery*, **2007**, 246, 655-62; discussion 662-4	7.8	796
81	Adverse-event rates: journals versus databases. *Lancet, The*, **2007**, 369, 171-2	40	2
80	Single agent fluorouracil for first-line treatment of advanced colorectal cancer as standard?. *Lancet, The*, **2007**, 370, 105-107	40	29

79	CAIRO and FOCUS Authors Reply. *Lancet, The*, **2007**, 370, 1905	40	2
78	Clinical Trials of Novel and Targeted Therapies: Endpoints, Trial Design, and Analysis. *Translational Medicine Series*, **2007**, 1-10		
77	Thymidylate synthase expression in colon carcinomas with microsatellite instability. *Clinical Cancer Research*, **2006**, 12, 2738-44	12.9	42
76	Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. *Journal of Clinical Oncology*, **2006**, 24, 4085-91	2.2	386
75	End points for adjuvant therapy trials: has the time come to accept disease-free survival as a surrogate end point for overall survival?. *Oncologist*, **2006**, 11, 624-9	5.7	59
74	Sam Wieand, PhD. *Journal of Clinical Oncology*, **2006**, 24, 4523-4525	2.2	8
73	Duffy-Santner confidence intervals for the two-stage three-outcome design. *Journal of Biopharmaceutical Statistics*, **2006**, 16, 875-80	1.3	1
72	Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial. *Journal of Clinical Oncology*, **2006**, 24, 3347-53	2.2	179
71	Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patients. *Gastroenterology*, **2006**, 131, 729-37	13.3	166
70	Randomized clinical trial of high-dose levamisole combined with 5-fluorouracil and leucovorin as surgical adjuvant therapy for high-risk colon cancer. *Clinical Colorectal Cancer*, **2006**, 6, 133-9	3.8	26
69	Current issues in adjuvant treatment of stage II colon cancer. *Annals of Surgical Oncology*, **2006**, 13, 887-98	3.1	81
68	Microsatellite instability accounts for tumor site-related differences in clinicopathologic variables and prognosis in human colon cancers. *American Journal of Gastroenterology*, **2006**, 101, 2818-25	0.7	60
67	Pick the Winner Designs in Phase II Cancer Clinical Trials. *Journal of Thoracic Oncology*, **2006**, 1, 5-6	8.9	4
66	Pick the Winner Designs in Phase II Cancer Clinical Trials. *Journal of Thoracic Oncology*, **2006**, 1, 5-6	8.9	3
65	An adaptive dose-finding design incorporating both toxicity and efficacy. *Statistics in Medicine*, **2006**, 25, 2365-83	2.3	134
64	Is en-bloc resection of locally recurrent rectal carcinoma involving the urinary tract indicated?. *Annals of Surgical Oncology*, **2006**, 13, 740-4	3.1	14
63	General and statistical hierarchy of appropriate biologic endpoints. *Oncology*, **2006**, 20, 5-9	1.8	43
62	Pick the winner designs in phase II cancer clinical trials. *Journal of Thoracic Oncology*, **2006**, 1, 5-6	8.9	3

61	FOLFOX for stage II colon cancer? A commentary on the recent FDA approval of oxaliplatin for adjuvant therapy of stage III colon cancer. *Journal of Clinical Oncology*, **2005**, 23, 3311-3	2.2	20
60	Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. *Journal of Clinical Oncology*, **2005**, 23, 8664-70	2.2	509
59	Clinical trial designs for prospective validation of biomarkers. *Molecular Diagnosis and Therapy*, **2005**, 5, 317-25		39
58	Clinical trial designs for predictive marker validation in cancer treatment trials. *Journal of Clinical Oncology*, **2005**, 23, 2020-7	2.2	406
57	5-Fluorouracil-based chemotherapy for advanced colorectal cancer in elderly patients: a north central cancer treatment group study. *Clinical Colorectal Cancer*, **2005**, 4, 325-31	3.8	34
56	A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. *Surgery*, **2005**, 138, 618-28; discussion 628-30	3.6	393
55	A pilot study of high-dose intraarterial cisplatin chemotherapy with concomitant accelerated radiotherapy for patients with previously untreated T4 and selected patients with T3N0-N3M0 squamous cell carcinoma of the upper aerodigestive tract. *Cancer*, **2005**, 103, 559-68	6.4	28
54	Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma. *Cancer*, **2005**, 104, 1871-84	6.4	32
53	Isolated loss of PMS2 expression in colorectal cancers: frequency, patient age, and familial aggregation. *Clinical Cancer Research*, **2005**, 11, 6466-71	12.9	49
52	Associations between plasma insulin-like growth factor proteins and C-peptide and quality of life in patients with metastatic colorectal cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2005**, 14, 1402-10	4	16
51	Adjuvant therapy for colon cancer--the pace quickens. *New England Journal of Medicine*, **2005**, 352, 2746-8	59.2	18
50	Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. *Journal of Clinical Oncology*, **2005**, 23, 9243-9	2.2	420
49	Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. *Journal of Clinical Oncology*, **2005**, 23, 9441-2	2.2	209
48	Dealing with a deluge of data: an assessment of adverse event data on North Central Cancer Treatment Group trials. *Journal of Clinical Oncology*, **2005**, 23, 9275-81	2.2	34
47	A comparison of laparoscopically assisted and open colectomy for colon cancer. *New England Journal of Medicine*, **2004**, 350, 2050-9	59.2	2808
46	Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?. *Journal of Clinical Oncology*, **2004**, 22, 1797-806	2.2	769
45	Phase III study of adjuvant chemotherapy and radiation therapy compared with chemotherapy alone in the surgical adjuvant treatment of colon cancer: results of intergroup protocol 0130. *Journal of Clinical Oncology*, **2004**, 22, 3277-83	2.2	77
44	Substitution of oral fluoropyrimidines for infusional fluorouracil with radiotherapy: how much data do we need?. *Journal of Clinical Oncology*, **2004**, 22, 2978-81	2.2	21

43	Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: a North Central Cancer Treatment Group Study. *Journal of Clinical Oncology*, **2004**, 22, 1572-82	2.2	112
42	Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. *Journal of Clinical Oncology*, **2004**, 22, 1209-14	2.2	888
41	Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. *Journal of Clinical Oncology*, **2004**, 22, 1785-96	2.2	357
40	Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741. *Cancer*, **2004**, 101, 2170-6	6.4	62
39	A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. *Journal of Clinical Oncology*, **2004**, 22, 23-30	2.2	1885
38	. *Annals of Surgery*, **2003**, 237, 502-508	7.8	29
37	Intraoperative radiotherapy for head and neck and skull base cancer. *Head and Neck*, **2003**, 25, 217-25; discussion 225-6	4.2	20
36	A phase I study of radiation therapy and twice-weekly gemcitabine and cisplatin in patients with locally advanced pancreatic cancer. *International Journal of Radiation Oncology Biology Physics*, **2003**, 55, 1305-10	4	27
35	Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. *New England Journal of Medicine*, **2003**, 349, 247-57	59.2	1641
34	Molecular diagnostics: assays, tissues, progress, and pitfalls. *Journal of Clinical Oncology*, **2003**, 21, 395-6	2.2	11
33	Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. *Journal of Clinical Oncology*, **2002**, 20, 1491-8	2.2	160
32	Issues in clinical trial design for tumor marker studies. *Seminars in Oncology*, **2002**, 29, 222-30	5.5	51
31	Use of intraoperative electron beam radiotherapy in the management of retroperitoneal soft tissue sarcomas. *International Journal of Radiation Oncology Biology Physics*, **2002**, 52, 469-75	4	141
30	Acute diarrhea during adjuvant therapy for rectal cancer: a detailed analysis from a randomized intergroup trial. *International Journal of Radiation Oncology Biology Physics*, **2002**, 54, 409-13	4	21
29	Impact of T and N substage on survival and disease relapse in adjuvant rectal cancer: a pooled analysis. *International Journal of Radiation Oncology Biology Physics*, **2002**, 54, 386-96	4	122
28	A new graphic for quality adjusted life years (Q-TWiST) survival analysis: the Q-TWiST plot. *Quality of Life Research*, **2002**, 11, 37-45	3.7	8
27	Efficacy and quality-of-life data are related in a phase II trial of oral chemotherapy in previously untreated patients with metastatic colorectal carcinoma. *Journal of Clinical Oncology*, **2002**, 20, 4574-80	2.2	32
26	Early detection of toxicity and adjustment of ongoing clinical trials: the history and performance of the North Central Cancer Treatment Group's real-time toxicity monitoring program. *Journal of Clinical Oncology*, **2002**, 20, 4591-6	2.2	31

25	Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. *Journal of Clinical Oncology*, **2002**, 20, 1043-8	2.2	442
24	Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer. *Journal of Clinical Oncology*, **2002**, 20, 1735-43	2.2	148
23	Short-term quality-of-life outcomes following laparoscopic-assisted colectomy vs open colectomy for colon cancer: a randomized trial. *JAMA - Journal of the American Medical Association*, **2002**, 287, 321-8	27.4	557
22	A flexible design for multiple armed screening trials. *Statistics in Medicine*, **2001**, 20, 1051-60	2.3	61
21	Comparison of artificial neural networks with other statistical approaches: results from medical data sets. *Cancer*, **2001**, 91, 1636-42	6.4	214
20	A three-outcome design for phase II clinical trials. *Contemporary Clinical Trials*, **2001**, 22, 117-25		63
19	Counting degrees of freedom in hierarchical and other richly-parameterised models. *Biometrika*, **2001**, 88, 367-379	2	93
18	A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. *New England Journal of Medicine*, **2001**, 345, 1091-7	59.2	784
17	Refining multimodal therapy for rectal cancer. *New England Journal of Medicine*, **2001**, 345, 690-2	59.2	54
16	Guidelines 2000 for colon and rectal cancer surgery. *Journal of the National Cancer Institute*, **2001**, 93, 583-96	9.7	1004
15	Impact of surgical and pathologic variables in rectal cancer: a United States community and cooperative group report. *Journal of Clinical Oncology*, **2001**, 19, 3895-902	2.2	168
14	Enhanced therapeutic potential of adoptive immunotherapy by in vitro CD28/4-1BB costimulation of tumor-reactive T cells against a poorly immunogenic, major histocompatibility complex class I-negative A9P melanoma. *Journal of Immunotherapy*, **2000**, 23, 430-7	5	34
13	A north central cancer treatment group Phase II trial of 9-aminocamptothecin in previously untreated patients with measurable metastatic colorectal carcinoma. *Cancer*, **2000**, 89, 1699-1705	6.4	13
12	PHASE II STUDY OF PACLITAXEL AND CISPLATIN FOR ADVANCED UROTHELIAL CANCER. *Journal of Urology*, **2000**, 164, 1538-1542	2.5	50
11	Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. *Archives of Pathology and Laboratory Medicine*, **2000**, 124, 979-94	5	882
10	Statistical issues in tumor marker studies. *Archives of Pathology and Laboratory Medicine*, **2000**, 124, 1011-5	5	26
9	Decrease in cranial nerve complications after radiosurgery for acoustic neuromas: a prospective study of dose and volume. *International Journal of Radiation Oncology Biology Physics*, **1999**, 43, 305-11	4	97
8	Sample size and design considerations for phase II clinical trials with correlated observations. *Contemporary Clinical Trials*, **1999**, 20, 242-52		8

7	The radial distance of extraprostatic extension of prostate carcinoma **1999**, 85, 2630-2637		118
6	The radial distance of extraprostatic extension of prostate carcinoma **1999**, 85, 2630		29
5	Acute treatment-related diarrhea during postoperative adjuvant therapy for high-risk rectal carcinoma. *International Journal of Radiation Oncology Biology Physics*, **1998**, 41, 593-8	4	56
4	A General Framework for Random Effects Survival Analysis in the Cox Proportional Hazards Setting. *Biometrics*, **1998**, 54, 1486	1.8	76
3	A flexible approach to time-varying coefficients in the Cox regression setting. *Lifetime Data Analysis* , **1997**, 3, 13-25	1.3	32
2	Robust Bayesian approaches for clinical trial monitoring. *Statistics in Medicine*, **1996**, 15, 1093-106	2.3	25
1	Gastrointestinal Cancers81-104		